Last reviewed · How we verify

R-Pharm — Portfolio Competitive Intelligence Brief

R-Pharm pipeline: 1 marketed, 0 filed, 11 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 11 Phase 3 3 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Tavanic Tavanic marketed Other
RPH-002 RPH-002 phase 3
Placebo Narlaprevir Placebo Narlaprevir phase 3 protease inhibitor NS3/4A protease Infectious Diseases
Placebo (100 ml) Placebo (100 ml) phase 3
Placebo (250 ml) Placebo (250 ml) phase 3
Ixabepilone + Capecitabine Ixabepilone + Capecitabine phase 3 Microtubule stabilizer + Antimetabolite β-tubulin (ixabepilone); Thymidylate synthase (capecitabine/5-FU) Oncology
Odelepan Odelepan phase 3 Other
RPH-051 RPH-051 phase 3 PDE4 inhibitor PDE4 Immunology
RPH-075 RPH-075 phase 3
standard concomitant therapy standard concomitant therapy phase 3 Oncology
Urotol® Urotol® phase 3 Muscarinic receptor antagonist M3 muscarinic receptor Urology
Uritos® Uritos® phase 3 Uricosuric agent / URAT1 inhibitor URAT1 (urate transporter 1) Rheumatology / Metabolic Disorders

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie (prior sponsor, Abbott) · 1 shared drug class
  2. Advenchen Pharmaceuticals, LLC. · 1 shared drug class
  3. Almirall, S.A. · 1 shared drug class
  4. Amgen · 1 shared drug class
  5. Arcutis Biotherapeutics, Inc. · 1 shared drug class
  6. Dr. Reddy's Laboratories Limited · 1 shared drug class
  7. Galderma R&D · 1 shared drug class
  8. AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for R-Pharm:

Cite this brief

Drug Landscape (2026). R-Pharm — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/r-pharm. Accessed 2026-05-13.

Related